Functional effects of the KCNQ modulators retigabine and XE991 in the rat urinary bladder

European Journal of Pharmacology

Volumn 638, Issue 1-3, 2010, Pages 121-127

  Rode, Frederik ^a   Svalø, Julie ^a,b   Sheykhzade, Majid ^b   Rønn, Lars Christian B ^a  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Bladder; KCNQ; KV7; M current; Retigabine; Urinary incontinence; XE991

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; CARBACHOL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL KCNQ; POTASSIUM CHLORIDE; RETIGABINE; 10,10-BIS(4-PYRIDINYLMETHYL)-9(10H)-ANTHRACENONE; ANTHRACENE DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMIC ACID DERIVATIVE; PHENYLENEDIAMINE DERIVATIVE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; BLADDER MUSCLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ELECTRIC FIELD; ELECTROSTIMULATION; MUSCLE ISOMETRIC CONTRACTION; MUSCLE TONE; MUSCLE TWITCH; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTILITY; SPRAGUE DAWLEY RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLADDER; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; IN VITRO STUDY; MUSCLE CONTRACTION; PHYSIOLOGY;

ANIMALS; ANTHRACENES; ANTICONVULSANTS; CARBACHOL; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; KCNQ POTASSIUM CHANNELS; MUSCLE CONTRACTION; PHENYLENEDIAMINES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHLORIDE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; IN VITRO TECHNIQUES;

EID: 77953536118     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.050     Document Type: Article

References (27)

1. Anderson U.A., Carson C., McCloskey K.D. KCNQ currents and their contribution to resting membrane potential and the excitability of interstitial cells of Cajal from the guinea pig bladder. J. Urol. 2009, 182:330-336.
2. Beisel K.W., Rocha-Sanchez S.M., Morris K.A., Nie L., Feng F., Kachar B., Yamoah E.N., Fritzsch B. Differential expression of KCNQ4 in inner hair cells and sensory neurons is the basis of progressive high-frequency hearing loss. J. Neurosci. 2005, 25:9285-9293.
3. Colli E., Digesu G.A., Olivieri L. Overactive bladder treatments in early phase clinical trials. Expert Opin. Investig. Drugs 2007, 16:999-1007.
4. Gillespie J.I. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. 2004, 93:478-483.
5. Greenwood I.A., Ohya S. New tricks for old dogs: KCNQ expression and role in smooth muscle. Br. J. Pharmacol. 2009, 156:1196-1203.
6. Herrera G.M., Etherton B., Nausch B., Nelson M.T. Negative feedback regulation of nerve-mediated contractions by KCa channels in mouse urinary bladder smooth muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R402-R409.
7. Herrmann W.M., Kern U., Aigner M. On the adverse reactions and efficacy of long-term treatment with flupirtine: preliminary results of an ongoing twelve-month study with 200 patients suffering from chronic pain states in arthrosis or arthritis. Postgrad. Med. J. 1987, 63(Suppl 3):87-103.
8. Hougaard C., Fraser M.O., Chien C., Bookout A., Katofiasc M., Jensen B.S., Rode F., Bitsch-Nørhave J., Teuber L., Thor K.B., Strøbaek D., Burgard E.C., Rønn L.C.B. A positive modulator of K Ca 2 and K Ca 3 channels, 4, 5-dichloro-1, 3-diethyl-1, 3-dihydro-benzoimidazol-2-one (NS4591), inhibits bladder afferent firing in vitro and bladder overactivity in vivo. J. Pharmacol. Exp. Ther. 2009, 328:28-39.
9. Jia Z., Bei J., Rodat-Despoix L., Liu B., Jia Q., Delmas P., Zhang H. NGF inhibits M/KCNQ currents and selectively alters neuronal excitability in subsets of sympathetic neurons depending on their M/KCNQ current background. J. Gen. Physiol. 2008, 131:575-587.
10. Johnston L., Carson C., Lyons A.D., Davidson R.A., McCloskey K.D. Cholinergic-induced Ca2+ signaling in interstitial cells of Cajal from the guinea pig bladder. Am. J. Physiol. Renal Physiol. 2008, 294:F645-F655.
11. Joshi S., Balan P., Gurney A.M. Pulmonary vasoconstrictor action of KCNQ potassium channel blockers. Respir. Res. 2006, 7:31.
12. Joshi S., Sedivy V., Hodyc D., Herget J., Gurney A.M. KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J. Pharmacol. Exp. Ther. 2009, 329:368-376.
13. Lagou M., Drake M.J., Markerink-VAN Ittersum M., DE Vente J., Gillespie J.I. Interstitial cells and phasic activity in the isolated mouse bladder. BJU Int. 2006, 98:643-650.
14. Lang P.M., Fleckenstein J., Passmore G.M., Brown D.A., Grafe P. Retigabine reduces the excitability of unmyelinated peripheral human axons. Neuropharmacology 2008, 54:1271-1278.
15. Mackie A.R., Brueggemann L.I., Henderson K.K., Shiels A.J., Cribbs L.L., Scrogin K.E., Byron K.L. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J. Pharmacol. Exp. Ther. 2008, 325:475-483.
16. McCallum L.A., Greenwood I.A., Tribe R.M. Expression and function of K(v)7 channels in murine myometrium throughout oestrous cycle. Pflugers Arch. 2009, 457:1111-1120.
17. McCloskey K.D., Gurney A.M. Kit positive cells in the guinea pig bladder. J. Urol. 2002, 168:832-836.
18. Ning Lo W., Liang W. Blockade of voltage-sensitive K+ channels increases contractility more in transverse than in longitudinal rat detrusor strips. Urology 2009, 73:400-404.
19. Ohya S., Asakura K., Muraki K., Watanabe M., Imaizumi Y. Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle. Am. J. Physiol. Gastrointest. Liver Physiol. 2002, 282:G277-G287.
20. Passmore G.M., Selyanko A.A., Mistry M., Al-Qatari M., Marsh S.J., Matthews E.A., Dickenson A.H., Brown T.A., Burbidge S.A., Main M., Brown D.A. KCNQ/M currents in sensory neurons: significance for pain therapy. J. Neurosci. 2003, 23:7227-7236.
21. Robbins J. KCNQ potassium channels: physiology, pathophysiology, and pharmacology. Pharmacol. Ther. 2001, 90:1-19.
22. Streng T., Christoph T., Andersson K.E. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J. Urol. 2004, 172:2054-2058.
23. Svalø J., Rode F., Sheykhzade M., Rønn L.C.B. Retigabine reduces bladder detrusor contractility. FASEB summer research conference - smooth muscle 2009, (Abstract. #26).
24. Wickenden A., Roeloffs R., McNaughton-Smith G., Rigdon G. KCNQ potassium channels: drug targets for the treatment of epilepsy and pain. Expert Op. Ther. Pat. 2004, 14:1-13.
25. Yeung S.Y.M., Greenwood I.A. Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells. Br. J. Pharmacol. 2005, 146:585-595.
26. Yeung S.Y.M., Pucovskỳ V., Moffatt J.D., Saldanha L., Schwake M., Ohya S., Greenwood I.A. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br. J. Pharmacol. 2007, 151:758-770.
27. Yeung S., Schwake M., Pucovskỳ V., Greenwood I. Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents. Br. J. Pharmacol. 2008, 155:62-72.